The KEYNOTE-042 trial showed that the anti-PD-1 antibody pembrolizumab as a first-line treatment improved overall survival (OS) compared to chemotherapy in patients with NSCLC [15]. This evidence concerns the gene RPL17 and non-small cell lung carcinoma.